Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIR178 plus PDR001 in advanced solid tumors and diffuse large B-cell lymphoma
NL-OMON55643Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of taminadenant, spartalizumab in Nonhematologic neoplasms, diffuse large B-cell lymphoma (DLBCL), renal cell carcinoma (RCC), pancreatic cancer (PC), transitional cell carcinoma (TCC), sponsored by Novartis. Started Dec 2017; status: active, not recruiting.
02
Drugs
taminadenantspartalizumab
03
Conditions
Nonhematologic neoplasmsdiffuse large B-cell lymphoma (DLBCL)renal cell carcinoma (RCC)pancreatic cancer (PC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON55643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55643.